Un médicament d'édition génique réduit le mauvais cholestérol de 62 pour cent lors d'un essai

28 mai 2026

Rapporté par l'IA

Une thérapie expérimentale appelée VERVE-102 a réduit le cholestérol LDL jusqu'à 62 pour cent après une dose unique dans le cadre d'une étude préliminaire de sécurité. Ces résultats proviennent d'un essai de phase I mené auprès de 35 patients souffrant d'hypercholestérolémie ou de maladies cardiovasculaires précoces. Les données ont été publiées cette semaine dans le New England Journal of Medicine.

Les chercheurs ont indiqué que le traitement semblait sûr, sans effets secondaires graves, même à la dose la plus élevée. Les participants n'ont ressenti qu'une légère augmentation temporaire des enzymes hépatiques. Le médicament utilise de l'ARNm encapsulé dans des nanoparticules pour modifier le gène PCSK9 dans les cellules du foie, réduisant ainsi de manière permanente la production d'une protéine qui augmente les niveaux de LDL.

Articles connexes

Scientific illustration of HELZ2 protein in the liver regulating cholesterol release.

UT Southwestern researchers identify HELZ2 protein that controls the liver’s release of cholesterol-carrying particles

25 mai 2026 Rapporté par l'IA Image générée par IA Vérifié par des faits

Scientists at UT Southwestern Medical Center report they have identified a protein, HELZ2, that acts as a key regulator of how many cholesterol-carrying particles the liver releases into the bloodstream by affecting the gene APOB. The study was published in the American Heart Association journal Circulation and could inform future research into heart disease and fatty liver disease.

Enlicitide pill reduces LDL cholesterol by 60% in phase 3 trial

An experimental oral pill called enlicitide lowered LDL cholesterol by about 60% in a large phase three clinical trial, according to results published in The New England Journal of Medicine. The trial, led by Dr. Ann Marie Navar at UT Southwestern Medical Center and sponsored by Merck, involved 2,909 participants mostly already on statins. If approved, the daily pill could improve access to effective cholesterol treatment.

DNA hairpin molecules lowered cholesterol by 47% in mice by silencing PCSK9, researchers report

1 mai 2026 Rapporté par l'IA Vérifié par des faits

Researchers from the University of Barcelona and the University of Oregon report that short DNA molecules known as polypurine reverse Hoogsteen hairpins (PPRHs) suppressed the PCSK9 gene and reduced blood cholesterol in a mouse model. In transgenic mice carrying the human PCSK9 gene, a single injection of one candidate (HpE12) cut plasma PCSK9 by 50% and total cholesterol by 47% three days later, according to findings published in Biochemical Pharmacology.

Santé

Virus injection halts pancreatic tumor growth in trial

Santé

UCLA scientists reverse liver damage in mice by removing zombie cells

Santé

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

Compound X clears Parkinson's proteins in mice brains

Researchers in Australia have found that a mysterious FDA-approved drug, called compound X, removes toxic alpha-synuclein proteins from the brains of mice with Parkinson's-like symptoms. The treatment improved the animals' balance and mobility by enhancing the brain's glymphatic waste disposal system. The findings were presented at a symposium in the UK.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

21 mai 2026 Rapporté par l'IA Vérifié par des faits

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

mardi 26 mai 2026 14h54

Un médicament d'édition génique réduit le mauvais cholestérol de 62 pour cent lors d'un essai

Articles connexes

UT Southwestern researchers identify HELZ2 protein that controls the liver’s release of cholesterol-carrying particles

Enlicitide pill reduces LDL cholesterol by 60% in phase 3 trial

DNA hairpin molecules lowered cholesterol by 47% in mice by silencing PCSK9, researchers report

Virus injection halts pancreatic tumor growth in trial

UCLA scientists reverse liver damage in mice by removing zombie cells

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

Compound X clears Parkinson's proteins in mice brains

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

USC researchers identify compounds targeting Alzheimer’s brain inflammation

Nanoparticles reduced amyloid-β and improved cognition in an Alzheimer’s mouse model, researchers report

Tenaya Therapeutics publishes RIDGE-1 data on TN-401 gene therapy

Trojan horse obesity drug boosts weight loss in mice

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

AI identifies breast cancer drug for multiple viruses

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

ACC and AHA release updated cholesterol management guidelines

Engineered antibody shrinks tumors body-wide in early cancer trial

Ce site utilise des cookies